Larimar Therapeutics Stock Analysis

Larimar Stock Analysis Notes

About 98.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 0.85. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Larimar Therapeutics recorded a loss per share of 1.32. The entity last dividend was issued on the 29th of May 2020. The firm had 1:12 split on the 29th of May 2020. Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreichs ataxia, a rare, progressive, and fatal genetic disease. Larimar Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 31 people. To find out more about Larimar Therapeutics contact Carole MD at 844 511 9056 or learn more at https://www.larimartx.com.

Larimar Therapeutics Investment Alerts

Larimar Therapeutics Upcoming and Recent Events

Larimar Largest EPS Surprises

View All Earnings Estimates

Larimar Therapeutics Environmental, Social, and Governance (ESG) Scores

Larimar Stock Institutional Investors

Note, although Larimar Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Larimar Market Capitalization

The company currently falls under 'Small-Cap' category with a current market capitalization of 145.48 M.

Larimar Profitablity

Management Efficiency

Larimar Therapeutics has return on total asset (ROA) of (0.2855) % which means that it has lost $0.2855 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.445) %, meaning that it created substantial loss on money invested by shareholders. Larimar Therapeutics' management efficiency ratios could be used to measure how well Larimar Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of 03/25/2025, Return On Tangible Assets is likely to drop to -0.42. In addition to that, Return On Capital Employed is likely to grow to -0.49. At this time, Larimar Therapeutics' Non Current Assets Total are relatively stable compared to the past year. As of 03/25/2025, Non Currrent Assets Other is likely to grow to about 795.7 K, while Other Current Assets are likely to drop slightly above 2.4 M.

Technical Drivers

As of the 25th of March, Larimar Therapeutics secures the Mean Deviation of 3.62, standard deviation of 4.73, and Risk Adjusted Performance of (0.19). In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Larimar Therapeutics, as well as the relationship between them. Please verify Larimar Therapeutics market risk adjusted performance and treynor ratio to decide if Larimar Therapeutics is priced some-what accurately, providing market reflects its recent price of 2.28 per share. Please also check out Larimar Therapeutics jensen alpha, which is currently at (0.96) to check the company can sustain itself at a future point.

Larimar Therapeutics Price Movement Analysis

Larimar Therapeutics Insider Trading Activities

Larimar Therapeutics Outstanding Bonds

Larimar Therapeutics Predictive Daily Indicators

Larimar Therapeutics Corporate Filings

Larimar Therapeutics Forecast Models

Larimar Therapeutics' time-series forecasting models are one of many Larimar Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Larimar Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Larimar Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Larimar shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Larimar Therapeutics. By using and applying Larimar Stock analysis, traders can create a robust methodology for identifying Larimar entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Larimar analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Larimar analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Larimar Therapeutics stock analysis indicators help investors evaluate how Larimar Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Larimar Therapeutics shares will generate the highest return on investment. By understating and applying Larimar Therapeutics stock analysis, traders can identify Larimar Therapeutics position entry and exit signals to maximize returns.

When running Larimar Therapeutics' price analysis, check to measure Larimar Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Larimar Therapeutics is operating at the current time. Most of Larimar Therapeutics' value examination focuses on studying past and present price action to predict the probability of Larimar Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Larimar Therapeutics' price. Additionally, you may evaluate how the addition of Larimar Therapeutics to your portfolios can decrease your overall portfolio volatility.